INSIGHTS ON CELL & GENE CLINICAL TRIALS
-
Regulatory Pathways — With Real-Life Examples — For Successful CGT Clinical Trials
Discover the most effective regulatory pathways used to support CGT development, including two real-life examples.
-
The Hidden Cost Of Preferred Vendors
Familiar vendors offer comfort — but at the cost of innovation, fit, and fresh thinking. Ease shouldn’t outweigh excellence when selecting partners for your clinical trial.
-
Navigating Biases In Clinical Trial Vendor Selection
Biases, often hidden, can distort vendor selection decisions. Recognizing and addressing them across individuals and teams leads to more objective, aligned, and successful clinical trial outcomes.
-
The Vendor Selection Blunder: An Expensive Oversight In Clinical Trials
Vendor selection isn’t just procedural — it shapes trial outcomes. Even with a solid process, missteps can ripple through timelines, budgets, and team morale. Choose wisely.
-
The 5 Dysfunctions Of Clinical Trial Vendor Selection — And How To Overcome Them
Vendor selection often fails due to five common dysfunctions. Identifying and addressing them early improves alignment, trust, and trial performance—avoiding costly delays.
-
Reframing Vendor Selection: Beyond Price And Past Relationships
An RFP is more than a budget tool — it’s a strategic communication document that guides vendors, clarifies expectations, and enables informed, data-driven sponsor decisions.
-
Why Use Scorecards To Make Vendor Selection Decisions
Scorecards enable structured, unbiased vendor selection by transforming complex clinical trial decisions into transparent, data-driven evaluations — ensuring operational excellence and regulatory compliance.
-
From Dollars To Debate: Why Clinical Trials Are At A Crossroad
Federal funding shifts in 2025 are impacting clinical research, with budget cuts and political scrutiny slowing innovation and threatening diversity in trial participation.
-
A Practical Guide To Patient Recruitment Excellence
Top-performing clinical trials treat recruitment as a science — thinking like patients, acting fast, and engaging communities with intention, not outdated tactics like bulletin board flyers.
-
Patients Favor Decentralized Clinical Trials
CISCRP’s 2025 survey reveals key clinical trial insights: altruism drives participation, trust in pharma lags, and most are comfortable with AI analyzing medical data.